BRG: Dividend Support And Updated Volume Guidance Will Drive Future Upside

Narrative Update

The analyst price target for Borregaard has been adjusted slightly from NOK 200 to around NOK 199.60, as analysts update their models with a lower discount rate, largely unchanged growth and margin assumptions, and a modestly higher future P/E, following a mix of recent upgrades and target cuts in Street research.

Analyst Commentary

Recent Street research around Borregaard has been mixed, with one upgrade and at least two cautious views. Together, these help explain the small adjustment in the average price target to around NOK 199.60.

Bullish Takeaways

Bullish analysts see enough support in their models to justify an upgrade, even with largely unchanged growth and margin assumptions. This suggests they are more comfortable with execution risk at current levels.
The modestly higher future P/E used in some updated models points to a view that the market could be willing to pay more for Borregaard’s earnings stream if the company delivers in line with expectations.
The use of a lower discount rate in some models supports a higher valuation for the same cash flow profile. Bullish analysts treat this as a reason to keep price targets relatively close to prior levels.
The fact that the average target is only slightly below NOK 200, even after target cuts, indicates that bullish analysts still see room for upside if Borregaard executes on its plans.

Bearish Takeaways

Bearish analysts have reduced their price targets. This points to concerns around either the level of earnings that can realistically be achieved or the multiple that investors may be willing to assign to those earnings.
A downgrade from a more positive rating to a more cautious stance signals that some analysts see a less attractive risk or reward balance at current prices, even if long term fundamentals are not materially changed in their models.
Target cuts indicate that certain analysts want an extra margin of safety on valuation. This suggests they are more focused on execution risks and the potential for earnings to fall short of prior expectations.
The combination of a downgrade and a target reduction shows that not all analysts are aligned on how to weigh growth potential against near term uncertainties. This divergence can keep the share price closer to the middle of their valuation ranges.

What's in the News

Borregaard issued new sales volume guidance for 2026, including expected BioSolutions volumes of approximately 340,000 tonnes for the full year, with continued growth mentioned in the agriculture segment. (Corporate guidance)
The company forecast BioMaterials sales volumes in 2026 in the range of 155,000 to 160,000 tonnes, compared with 146,000 tonnes in 2025. It also expects sales volume of highly specialized grades to be slightly above the 2025 level. (Corporate guidance)
For Fine Chemicals, Borregaard expects bioethanol sales prices to be broadly in line with 2025 levels and sales volumes for Fine Chemical intermediates to be higher than in 2025. (Corporate guidance)
First quarter 2026 BioSolutions sales volume is expected to be around 80,000 tonnes. This is described as more or less in line with the 81,000 tonnes in the first quarter of 2025. The average BioMaterials sales price in sales currency is expected to be 3% to 4% lower in the first half of 2026 compared with the second half of 2025. (Corporate guidance)
The Board of Directors decided to propose an ordinary dividend for 2025 of NOK 4.75 per share, with an estimated total dividend payment of NOK 474 million, subject to approval at the Annual General Meeting on 16 April 2026. The share is planned to trade ex dividend on 17 April 2026, with payment scheduled for 27 April 2026 to shareholders registered as of 20 April 2026. (Board meeting and dividend announcement)

Valuation Changes

Fair Value: NOK 200.00 to NOK 199.60, a very small adjustment that keeps the implied upside essentially unchanged.
Discount Rate: 7.01% to 6.94%, a slight reduction that generally supports a higher valuation for the same cash flow profile.
Revenue Growth: 5.48% to 5.48%, effectively unchanged. The long term top line outlook in analyst models remains consistent.
Net Profit Margin: 13.67% to 13.67%, also effectively unchanged. This indicates similar profitability assumptions to earlier models.
Future P/E: 19.61x to 19.73x, a modest uplift that signals a slightly higher assumed earnings multiple in updated analyses.

6 views

Key Takeaways

Strong demand for green products and high-value specialties is expected to boost sales and margins, driving revenue growth for Borregaard.
Operational improvements and currency hedging could stabilize revenue and enhance financial resilience despite trade and currency challenges.
Trade tensions and increased expenses could affect Borregaard's revenue and margins, while reliance on agriculture exposes it to sector-specific risks.

Catalysts

About Borregaard

Engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally.What are the underlying business or industry changes driving this perspective?

Strong sales in the agriculture segment, driven by the increasing demand for green and biocontrol products, are expected to positively impact revenue growth and EBITDA margins.
The favorable product mix in BioSolutions, particularly with high-value specialty products, is anticipated to boost overall earnings and contribute to higher net margins.
Tariffs and trade dynamics, although presenting some uncertainty, might have less impact on Borregaard due to its highly specialized products and diverse market presence, thereby potentially stabilizing revenue despite global trade fluctuations.
Continuous investment and focus on operational improvements, such as the electrification of biopolymer spray dryers to reduce energy costs, are likely to enhance net margins over time.
Ongoing currency hedging strategies and anticipated positive currency effects are expected to have a favorable impact on EBITDA and earnings, providing financial resilience amidst currency volatility.

Borregaard Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Borregaard's revenue will grow by 5.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.0% today to 13.7% in 3 years time.
Analysts expect earnings to reach NOK 1.2 billion (and earnings per share of NOK 12.41) by about April 2029, up from NOK 620.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting NOK1.5 billion in earnings, and the most bearish expecting NOK1.0 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.8x on those 2029 earnings, down from 28.2x today. This future PE is lower than the current PE for the GB Chemicals industry at 28.2x.
Analysts expect the number of shares outstanding to grow by 0.22% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.94%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The introduction of a 10% tariff on imports from Norway into the U.S. could impact Borregaard's revenues from their U.S. sales, as 10% of their sales last year came from Norway to the U.S. The lower volume of exports due to these tariffs might have a negative effect on revenue.
Increased supply of advanced bioethanol in Europe, based on agricultural waste, is expected to lead to significantly lower sales prices for Borregaard's bioethanol, which could decrease revenue and impact net margins in the Fine Chemicals segment.
Higher wood and logistical costs have increased expenses for Borregaard, which could limit the company's ability to increase net margins and impact overall profitability.
Potential negative effects on global GDP growth from tariffs and trade tensions could ultimately reduce demand for Borregaard's products, affecting revenue growth across its segments.
The strong current reliance on the agricultural sector for BioSolutions' revenues might expose Borregaard to risks associated with any downturn in agriculture or shifts in customer demand, potentially impacting revenues and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of NOK199.6 for Borregaard based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of NOK240.0, and the most bearish reporting a price target of just NOK175.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NOK9.1 billion, earnings will come to NOK1.2 billion, and it would be trading on a PE ratio of 19.8x, assuming you use a discount rate of 6.9%.
Given the current share price of NOK175.2, the analyst price target of NOK199.6 is 12.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Borregaard?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Adjust Borregaard Price Target and Valuation Following Recent Updates and Ongoing Developments